Return to search

Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia

Cancer cells use the interaction between immune-checkpoint receptor programmed cell death protein 1 (PD-1) on activated T cells and programmed cell death ligand 1 (PD-L1) on tumor cells and various cell types of the tumor microenvironment to evade immune surveillance. Blocking the interaction between PD-1 and PD-L1 with checkpoint inhibitors can improve T-cell reactions and mediate efficient antitumor activity in a variety of solid tumors including melanoma. However, clinical data from patients with myeloid diseases that are treated with these agents are limited to clinical trials in advanced disease. Pembrolizumab (PEM) is a humanized monoclonal antibody of the immunoglobulin G4/κ isotype designed to block PD-1/PD-L1 interactions and is approved for various solid tumors including advanced melanoma.

Identiferoai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:34908
Date09 August 2019
CreatorsKubasch, Anne Sophie, Wehner, Rebekka, Bazzurri, Serena, Tunger, Antje, Stasik, Sebastian, Garzarolli, Marlene, Meinel, Jörn, Baretton, Gustavo, Meier, Friedegund, Thiede, Christian, Schmitz, Marc, Platzbecker, Uwe
PublisherAmerican Society of Hematology
Source SetsHochschulschriftenserver (HSSS) der SLUB Dresden
LanguageEnglish
Detected LanguageEnglish
Typeinfo:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text
Rightsinfo:eu-repo/semantics/openAccess
Relation2473-9537, 10.1182/bloodadvances.2017014811

Page generated in 0.0022 seconds